Announced
Completed
Financials
Tags
Private
Friendly
Acquisition
Single Bidder
health care
Majority
Biotechnology
Domestic
United States
biotechnology
genetics
Completed
Synopsis
Gilead-backed Kite, a global biopharmaceutical company, completed the acquisition of Tmunity Therapeutics, a clinical-stage, private biotech company. Financial terms were not disclosed. “Kite has demonstrated an ability to globally scale cell therapy and address the unique challenges and opportunities that cell therapy represents, which are quite different in material ways than traditional pharmaceutical or biotech approaches. Kite’s singular focus on cell therapy makes them unique and particularly nimble,” Carl June, Tmunity Founder.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.